Shanghai Yizhong Pharmaceutical Past Earnings Performance
Past criteria checks 1/6
Shanghai Yizhong Pharmaceutical has been growing earnings at an average annual rate of 95.6%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 94.8% per year. Shanghai Yizhong Pharmaceutical's return on equity is 9.1%, and it has net margins of 40.3%.
Key information
95.6%
Earnings growth rate
101.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 94.8% |
| Return on equity | 9.1% |
| Net Margin | 40.3% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Shanghai Yizhong Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 337 | 136 | 164 | 25 |
| 31 Dec 23 | 360 | 162 | 153 | 22 |
| 30 Sep 23 | 349 | 169 | 145 | 20 |
| 31 Mar 23 | 294 | 167 | 118 | 9 |
| 31 Dec 22 | 236 | 143 | 101 | 8 |
| 30 Sep 22 | 170 | 120 | 73 | 5 |
| 30 Jun 22 | 76 | 69 | 29 | 7 |
| 31 Mar 22 | 38 | 32 | 22 | 11 |
| 31 Dec 21 | 4 | -4 | 18 | 13 |
| 30 Sep 21 | 0 | -27 | 16 | 18 |
| 30 Jun 21 | 0 | -24 | 13 | 19 |
| 31 Mar 21 | 0 | -22 | 13 | 17 |
| 31 Dec 20 | 0 | -22 | 12 | 18 |
| 31 Dec 19 | 0 | -315 | 144 | 179 |
| 31 Dec 18 | 0 | -13 | 7 | 14 |
Quality Earnings: 688091 has a high level of non-cash earnings.
Growing Profit Margin: 688091's current net profit margins (40.3%) are lower than last year (56.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688091 has become profitable over the past 5 years, growing earnings by 95.6% per year.
Accelerating Growth: 688091's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 688091 had negative earnings growth (-18.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.1%).
Return on Equity
High ROE: 688091's Return on Equity (9.1%) is considered low.